Dr Reddys Laboratories has entered into a definitive asset purchase
agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy's would sell
its US and select territory rights for ZEMBRACE SYMTOUCH (sumatriptan injection) 3 mg and
TOSYMRA (sumatriptan nasal spray) 10 mg, (formerly referred to as "DFN-02"), which are
commercialized through its wholly owned subsidiary, Promius Pharma, LLC.
Under the agreement, Dr.Reddy's will receive U.S.$70 million as upfront consideration, U.S.$40.5 million in near term milestones and additional financial considerations including, existing contractual obligation and inventory. Subsequently, Dr. Reddy's will receive sales based royalties on a quarterly basis.
The closing of the transaction is subject to various customary closing conditions including antitrust review under Hart-Scott-Rodino Act.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
